A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus Peginterferon PegIFNα-2a (Pegasys®) and ribavirin (Copegus®) triple therapy in chronic hepatitis C genotype-1 infected subjects who are co-infected with human immunodeficiency virus type 1 (HIV-1).